ACLARIS THERAPEUTICS INC. - COMMON STOCK

2.1800

14-November-24 16:45:00

15 minutes delayed

Stocks

-0.2600

-10.66%

Today's range

2.1800 - 2.4700

ISIN

N/A

Source

NASDAQ

Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

15 Mar 2021 07:00:01 By Nasdaq GlobeNewswire
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

25 Feb 2021 07:00:04 By Nasdaq GlobeNewswire
Aclaris Therapeutics to Participate in Upcoming Investor Conferences

22 Feb 2021 07:00:00 By Nasdaq GlobeNewswire
Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

10 Feb 2021 07:00:00 By Nasdaq GlobeNewswire
Aclaris Announces Pricing of Public Offering of Common Stock

20 Jan 2021 08:45:00 By Nasdaq GlobeNewswire
Aclaris Announces Proposed Public Offering of Common Stock

19 Jan 2021 16:01:00 By Nasdaq GlobeNewswire
Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis

19 Jan 2021 07:00:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
4
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.